ArticleBritish journal of cancer2008
Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.British journal of cancer · 2010Pooled it
- Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.The Cochrane database of systematic reviews · 2009Pooled it
- Erythropoietin in Tumor Immunity: Mechanistic Evidence, Clinical Cautions, and Translational Opportunities.Cancers · 2026Review
- Complex Genomic Alterations in TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia Involving EPOR/JAK2 Amplification, ERG Copy Gains, and TCF3 Deletion.Genes, chromosomes & cancer · 2026Article
- Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma.Journal of experimental & clinical cancer research : CR · 2025Article
- ΗΙF1α, EGR1 and SP1 co-regulate the erythropoietin receptor expression under hypoxia: an essential role in the growth of non-small cell lung cancer cells.Cell communication and signaling : CCS · 2019Article
- Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor.Cancer cell international · 2017Article
- Article
- Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population.Journal of biomedical research · 2014Article
- Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- Progress in detecting cell-surface protein receptors: the erythropoietin receptor example.Annals of hematology · 2014Review
- Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.Journal of cellular biochemistry · 2014Review
- Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2013Article
- The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection.Kidney international · 2013Article
- Erythropoietin.Cold Spring Harbor perspectives in medicine · 2013Review
- Article
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.British journal of cancer · 2012Review
- The effect of erythropoietin on normal and neoplastic cells.Biologics : targets & therapy · 2012Article
- Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2011Review
- Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.Anticancer research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin receptor (EpoR) has been reported to be overexpressed in tumours and has raised safety concerns regarding the use of erythropoiesis-stimulating agents (ESAs) to treat anaemia in cancer patients. To investigate the potential for EpoR to be overexpressed in tumours, we have evaluated human tumours for amplification of the EPOR locus, levels of EPOR transcripts, and expression of surface EpoR protein. Gene amplification analysis of 1083 solid tumours found that amplification of the EPOR locus was rare with frequencies similar to other non-oncogenes. EPOR transcript levels in tumours and tumour cell lines were low in comparison with bone marrow and were equivalent to, or lower than, levels in normal tissues of tumour origin. Although EpoR mRNA was detected in some tumour lines, no EpoR could be detected on the cell surface using (125)I-Epo binding studies. This may be due to the lack of EpoR protein expression or lack of cell-surface-trafficking factors, such as Jak2. Taken together, we have found no evidence that EpoR is overexpressed in tumours or gets to the surface of tumour cells. This suggests that there is no selective advantage for tumours to overexpress EpoR and questions the functional relevance of EpoR gene transcription in tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.